glp-1 agonist benefits EASD 2018: of GIP/GLP-1 receptor co-agonists in T2D Cardiovascular benefits of glucagon-like peptide-1
Description
The actual evaluation of cardiovascular benefits will be achieved with the completion of the Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results (LEADER) trial, which enrolled 9,340 T2D patients randomized for treatment with liraglutide or placebo for an estimated period of 5 years (ClinicalTrials.gov Identifier: NCT01179048)
Other studies are also testing to see whether drugs like Ozempic might be helpful in the setting of substance abuse.
PMID: 36462999 Contreras C et al (2017): Traveling from the hypothalamus to the adipose tissue: The thermogenic pathway
Front Neurosci (2021) 15:660942
Each modality targets different aspects of the gut-brain axis, highlighting the interconnectedness of gut health, metabolic regulation, and appetite control
10.1016/j.mocell.2023.12.002 25 GottsJ
